Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00134420 · ClinicalTrials.gov registry record · Phase 3
Growth Hormone and Chromosome 18q- and Abnormal Growth
A Phase 3 study of Growth Hormone Deficiency and Loss of Chromosome 18q, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00134420 is a Phase 3 study of Growth Hormone Deficiency and Loss of Chromosome 18q that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 20 participants, below the 386-participant average among 16 other Growth Hormone Deficiency trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00134420, a Phase 3 study of Growth Hormone Deficiency and Loss of Chromosome 18q, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
We, the investigators at the University of Texas Health Science Center at San Antonio, want to learn if height and IQ (intelligence quotient) scores are improved by growth hormone (GH) treatment in children with chromosome 18 deletions and abnormal growth. Data from a previous study showed that growth hormone improved height in all children with 18q- and growth hormone deficiency. In addition, most of the study participants on growth hormone treatment showed an increase in IQ scores.
Conditions Studied
Interventions
- DRUG Nutropin AQ
- PROCEDURE Arginine and Clonidine Stimulation Testing
- PROCEDURE Growth Factors Laboratory Testing
- PROCEDURE Neuropsychological Testing
Study Locations (1)
Texas
- The University of Texas Health Science Center at San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2001-02 |
| Est. Completion | 2005-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00134420
The ClinicalTrials.gov registry entry for NCT00134420 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 386-participant average among 16 other Growth Hormone Deficiency trials with a reported enrollment target (95% lower). The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Growth Hormone Deficiency appearing as the primary indexed condition, and to 4 interventions - of which Nutropin AQ is the first listed.
NCT00134420 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00134420 about?
NCT00134420 is a clinical study titled "Growth Hormone and Chromosome 18q- and Abnormal Growth". We, the investigators at the University of Texas Health Science Center at San Antonio, want to learn if height and IQ (intelligence quotient) scores are improved by growth hormone (GH) treatment in children with chromosome 18 deletions and abnormal growth. Data from a previous study showed that grow...
What is the current status of trial NCT00134420?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2001-02. Estimated completion is 2005-06.
What conditions does trial NCT00134420 study?
This clinical trial studies the following conditions: Growth Hormone Deficiency, Loss of Chromosome 18q.
What interventions are being tested in trial NCT00134420?
The interventions under investigation include: Nutropin AQ (DRUG), Arginine and Clonidine Stimulation Testing (PROCEDURE), Growth Factors Laboratory Testing (PROCEDURE), Neuropsychological Testing (PROCEDURE).
Who is sponsoring clinical trial NCT00134420?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00134420 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Growth Hormone Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Genotropin Study Assessing Use of Injection Pen
COMPLETED · Phase 3
-
A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency
COMPLETED · Phase 3
-
A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA
RECRUITING
-
A Post-Authorisation Safety Study (PASS) of Patients Treated With Lonapegsomatropin
RECRUITING
-
Effects of GH and Lirglutide on AgRP
RECRUITING · Phase 4
-
Chromosome 18 Clinical Research Center
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.